VanEck Associates’s Emergent Biosolutions EBS Stock Holding History

VanEck Associates’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-233	Closed	-$22K	–	1287
2021 Q1	$22K	Buy	+233	New	+$23.9K	﹤0.01%	1173

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VanEck Associates's EBS Position: Q2 2021 in Review

VanEck Associates sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 233 shares — an estimated $22K sold.

VanEck Associates first reported a position in EBS in Q1 2021 and held it in 1 quarter. The position peaked at $22K in Q1 2021. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

VanEck Associates reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
VanEck Associates sold 233 Emergent Biosolutions shares in Q2 2021, an estimated $22K.
VanEck Associates first reported a position in Emergent Biosolutions in Q1 2021 and held it in 1 quarter.
VanEck Associates's Emergent Biosolutions position peaked at $22K in Q1 2021.
290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on VanEck Associates's 13F filing for Q2 2021, filed 10 Aug 2021.